Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07291076 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

A Phase 1 study of Hepatocellular Carcinoma (HCC), sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 1
Development phase
129
Enrollment target
20
Study locations

NCT07291076 is a Phase 1 study of Hepatocellular Carcinoma (HCC) that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 129 participants, below the 343-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07291076, a Phase 1 study of Hepatocellular Carcinoma (HCC), is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 1
Development phase
129 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)

Conditions Studied

Hepatocellular Carcinoma (HCC)

Interventions

  • DRUG Bevacizumab
  • DRUG Atezolizumab
  • DRUG Ipilimumab
  • DRUG Pumitamig

Study Locations (20)

Tennessee

  • Local Institution - 0022 - Nashville
  • Local Institution - 0102 - Nashville

New South Wales

  • Local Institution - 0024 - Camperdown
  • Local Institution - 0033 - Westmead

Santiago Metropolitan

  • Local Institution - 0064 - Santiago
  • Local Institution - 0106 - Santiago Region Metropolitana

California

  • Local Institution - 0070 - Los Angeles

Illinois

  • Local Institution - 0107 - Chicago

New Jersey

  • John Theurer Cancer Center at Hackensack University Medical Center - Hackensack

New York

  • Local Institution - 0100 - Great Neck

Oregon

  • Local Institution - 0080 - Portland

Trial Details

FieldValue
Enrollment Target 129 participants
Start Date 2026-03-31
Est. Completion 2031-10-14
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07291076

The ClinicalTrials.gov registry entry for NCT07291076 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 343-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (62% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatocellular Carcinoma (HCC) appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.

NCT07291076 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Tennessee, New South Wales, Santiago Metropolitan.

Frequently Asked Questions

What is clinical trial NCT07291076 about?

NCT07291076 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)". The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)

What is the current status of trial NCT07291076?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2026-03-31. Estimated completion is 2031-10-14.

What conditions does trial NCT07291076 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma (HCC).

What interventions are being tested in trial NCT07291076?

The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Ipilimumab (DRUG), Pumitamig (DRUG).

Who is sponsoring clinical trial NCT07291076?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07291076 being conducted?

This trial has 20 study locations across California, Illinois, New Jersey, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma (HCC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatocellular Carcinoma (HCC)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.